Laboratory of Small Animal Internal Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan.
Azabu University Veterinary Teaching Hospital, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan.
J Vet Med Sci. 2022 Jan 24;84(1):142-148. doi: 10.1292/jvms.20-0352. Epub 2021 Dec 6.
A 5-year-old female cat with nonregenerative anemia and thrombocytopenia was diagnosed with myelodysplastic syndromes (MDS), since peripheral blood and bone marrow (BM) examination revealed various dysplasias and a blast ratio of 19%. Chemotherapy with azacytidine (AZA; 70-35 mg/m, 3-5 days, three cycles) and treatment with prednisolone, antibiotics, and vitamin K2, and blood transfusion were performed. On day 106, blast cells and dysplasia had decreased in the BM, and the cat remained alive for at least 1,474 days. This report is the first on feline MDS treated with AZA, suggesting appropriate drug dosage, interval and effective combination should be investigated and the pharmacological and cell biological mechanisms needs to be elucidated in the future.
一只 5 岁的雌性猫患有非再生性贫血和血小板减少症，被诊断为骨髓增生异常综合征（MDS），因为外周血和骨髓（BM）检查显示存在各种发育异常和 19%的原始细胞比例。使用阿扎胞苷（AZA；70-35mg/m，3-5 天，三个周期）进行化疗，并使用泼尼松龙、抗生素和维生素 K2 进行治疗以及输血。在第 106 天，BM 中的原始细胞和发育异常减少，猫至少存活了 1474 天。这是第一例用 AZA 治疗猫 MDS 的报告，提示未来需要研究适当的药物剂量、间隔和有效联合，并阐明其药理和细胞生物学机制。
